Aristea initiates 2b trial of palmoplantar pustulosis candidate

Aristea Therapeutics has dosed the first patient in a phase 2b trial of its palmoplantar pustulosis candidate RIST4721, the company announced in a press release.

A CXCR2 antagonist, RIST4721 is in development for the treatment of multiple inflammatory diseases, including the rare chronic skin condition palmoplantar pustulosis (PPP), which is characterized by recurrent sterile pustules on the palms of the hands and soles of the feet.

The phase 2b, randomized, double-blind, placebo controlled, 12-week, dose ranging trial is recruiting patients within North America.

“This is a promising time in the company’s progress, and we are glad to have commenced our phase 2b trial of RIST4721 in PPP,” James M. Mackay, PhD, president and CEO of Aristea, said in the release. “This is a condition with no approved therapies in the United States or Europe, and we are excited to keep moving forward in developing a potential treatment option for these patients in need.”